S&P 500   3,827.16 (-0.37%)
DOW   30,800.91 (-0.63%)
QQQ   326.83 (+0.43%)
AAPL   142.74 (+2.64%)
MSFT   227.36 (+0.62%)
FB   275.81 (+0.48%)
GOOGL   1,876.54 (-0.85%)
AMZN   3,295.33 (+0.09%)
TSLA   871.30 (+2.91%)
NVDA   541.15 (-1.34%)
BABA   260.94 (+0.90%)
CGC   33.13 (-1.98%)
GE   10.96 (-1.35%)
MU   80.57 (-2.08%)
AMD   93.43 (+0.69%)
NIO   60.25 (-2.74%)
T   28.81 (-0.41%)
F   11.08 (-3.82%)
ACB   10.31 (-3.19%)
BA   201.30 (-2.21%)
DIS   170.76 (-1.17%)
NFLX   558.64 (-1.16%)
GILD   66.69 (-0.37%)
S&P 500   3,827.16 (-0.37%)
DOW   30,800.91 (-0.63%)
QQQ   326.83 (+0.43%)
AAPL   142.74 (+2.64%)
MSFT   227.36 (+0.62%)
FB   275.81 (+0.48%)
GOOGL   1,876.54 (-0.85%)
AMZN   3,295.33 (+0.09%)
TSLA   871.30 (+2.91%)
NVDA   541.15 (-1.34%)
BABA   260.94 (+0.90%)
CGC   33.13 (-1.98%)
GE   10.96 (-1.35%)
MU   80.57 (-2.08%)
AMD   93.43 (+0.69%)
NIO   60.25 (-2.74%)
T   28.81 (-0.41%)
F   11.08 (-3.82%)
ACB   10.31 (-3.19%)
BA   201.30 (-2.21%)
DIS   170.76 (-1.17%)
NFLX   558.64 (-1.16%)
GILD   66.69 (-0.37%)
S&P 500   3,827.16 (-0.37%)
DOW   30,800.91 (-0.63%)
QQQ   326.83 (+0.43%)
AAPL   142.74 (+2.64%)
MSFT   227.36 (+0.62%)
FB   275.81 (+0.48%)
GOOGL   1,876.54 (-0.85%)
AMZN   3,295.33 (+0.09%)
TSLA   871.30 (+2.91%)
NVDA   541.15 (-1.34%)
BABA   260.94 (+0.90%)
CGC   33.13 (-1.98%)
GE   10.96 (-1.35%)
MU   80.57 (-2.08%)
AMD   93.43 (+0.69%)
NIO   60.25 (-2.74%)
T   28.81 (-0.41%)
F   11.08 (-3.82%)
ACB   10.31 (-3.19%)
BA   201.30 (-2.21%)
DIS   170.76 (-1.17%)
NFLX   558.64 (-1.16%)
GILD   66.69 (-0.37%)
S&P 500   3,827.16 (-0.37%)
DOW   30,800.91 (-0.63%)
QQQ   326.83 (+0.43%)
AAPL   142.74 (+2.64%)
MSFT   227.36 (+0.62%)
FB   275.81 (+0.48%)
GOOGL   1,876.54 (-0.85%)
AMZN   3,295.33 (+0.09%)
TSLA   871.30 (+2.91%)
NVDA   541.15 (-1.34%)
BABA   260.94 (+0.90%)
CGC   33.13 (-1.98%)
GE   10.96 (-1.35%)
MU   80.57 (-2.08%)
AMD   93.43 (+0.69%)
NIO   60.25 (-2.74%)
T   28.81 (-0.41%)
F   11.08 (-3.82%)
ACB   10.31 (-3.19%)
BA   201.30 (-2.21%)
DIS   170.76 (-1.17%)
NFLX   558.64 (-1.16%)
GILD   66.69 (-0.37%)
Log in
NASDAQ:BLUE

bluebird bio Stock Forecast, Price & News

$46.50
-0.14 (-0.30 %)
(As of 01/25/2021 12:15 PM ET)
Add
Compare
Today's Range
$46.21
Now: $46.50
$48.04
50-Day Range
$42.46
MA: $46.24
$52.33
52-Week Range
$38.95
Now: $46.50
$94.50
Volume30,889 shs
Average Volume1.16 million shs
Market Capitalization$3.09 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.89
bluebird bio, Inc., a biotechnology company, engages in researching, developing, and commercializing of transformative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin for the treatment of Ã-thalassemia and sickle cell disease; and Lenti-D for the treatment of cerebral adrenoleukodystrophy. The company's product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Bristol-Myers Squibb to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets; Forty Seven, Inc. to pursue clinical proof-of-concept for an antibody-based conditioning regimen; and Novo Nordisk A/S to develop in vivo genome editing treatments for genetic diseases, as well as clinical trial collaboration with Magenta Therapeutics. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
bluebird bio logo

MarketRank

Overall MarketRank

1.80 out of 5 stars

Medical Sector

134th out of 1,923 stocks

Biological Products, Except Diagnostic Industry

14th out of 177 stocks

Analyst Opinion: 4.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BLUE
CUSIPN/A
Phone339-499-9300
Employees1,090
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$44.67 million
Book Value$23.22 per share

Profitability

Net Income$-789,610,000.00
Net Margins-256.84%

Miscellaneous

Market Cap$3.09 billion
Next Earnings Date2/16/2021 (Estimated)
OptionableOptionable
$46.50
-0.14 (-0.30 %)
(As of 01/25/2021 12:15 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BLUE News and Ratings via Email

Sign-up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











bluebird bio (NASDAQ:BLUE) Frequently Asked Questions

How has bluebird bio's stock price been impacted by COVID-19 (Coronavirus)?

bluebird bio's stock was trading at $61.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BLUE stock has decreased by 24.3% and is now trading at $46.59.
View which stocks have been most impacted by COVID-19
.

Is bluebird bio a buy right now?

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 7 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" bluebird bio stock.
View analyst ratings for bluebird bio
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than bluebird bio?

Wall Street analysts have given bluebird bio a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but bluebird bio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Nick Leschly's approval rating as bluebird bio's CEO?

66 employees have rated bluebird bio CEO Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among bluebird bio's employees.

When is bluebird bio's next earnings date?

bluebird bio is scheduled to release its next quarterly earnings announcement on Tuesday, February 16th 2021.
View our earnings forecast for bluebird bio
.

How were bluebird bio's earnings last quarter?

bluebird bio, Inc. (NASDAQ:BLUE) released its quarterly earnings data on Monday, November, 9th. The biotechnology company reported ($2.94) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.02) by $0.08. The biotechnology company earned $19.27 million during the quarter, compared to analyst estimates of $25.47 million. bluebird bio had a negative trailing twelve-month return on equity of 45.78% and a negative net margin of 256.84%. bluebird bio's revenue for the quarter was up 116.3% on a year-over-year basis. During the same quarter last year, the firm earned ($3.73) EPS.
View bluebird bio's earnings history
.

What price target have analysts set for BLUE?

19 brokerages have issued 1 year target prices for bluebird bio's shares. Their forecasts range from $50.00 to $123.00. On average, they expect bluebird bio's stock price to reach $78.53 in the next year. This suggests a possible upside of 68.6% from the stock's current price.
View analysts' price targets for bluebird bio
or view Wall Street analyst' top-rated stocks.

Who are some of bluebird bio's key competitors?

What other stocks do shareholders of bluebird bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), (CELG), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).

Who are bluebird bio's key executives?

bluebird bio's management team includes the following people:
  • Mr. Nick Leschly, Pres, CEO & Director (Age 48, Pay $1.09M)
  • Mr. William D. Baird III, Chief Financial Officer (Age 49, Pay $808.89k)
  • Mr. Jason F. Cole, Chief Operating & Legal Officer and Sec. (Age 48, Pay $619.8k)
  • Dr. Philip D. Gregory, Chief Scientific Officer (Age 50, Pay $660.8k)
  • Dr. David M. Davidson, Chief Medical Officer (Age 57, Pay $705k)
  • Ms. Katy Burnett, Interim Principal Accounting Officer, Sr. Director & Global Controller (Age 45)
  • Dr. Derek Adams Ph.D., Chief Technology & Manufacturing Officer
  • Ms. Ingrid Goldberg, VP of Investor Relations
  • Ms. Elizabeth Pingpank, Director of Corp. Communications
  • Ms. Kathleen A. Wilkinson, Chief People Officer (Age 49)

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

Who are bluebird bio's major shareholders?

bluebird bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (0.64%), Frontier Capital Management Co. LLC (0.19%), DNB Asset Management AS (0.02%), Boyd Watterson Asset Management LLC OH (0.02%), Pacer Advisors Inc. (0.00%) and NuWave Investment Management LLC (0.00%). Company insiders that own bluebird bio stock include Alison Cecily Finger, David Davidson, Jason Cole, Jeffrey T Walsh, Joanne Smith-Farrell, Katy Burnett, Kory James Wentworth, Nick Leschly, Philip D Gregory and William D Baird III.
View institutional ownership trends for bluebird bio
.

Which major investors are buying bluebird bio stock?

BLUE stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Frontier Capital Management Co. LLC, Boyd Watterson Asset Management LLC OH, Pacer Advisors Inc., NuWave Investment Management LLC, and DNB Asset Management AS.
View insider buying and selling activity for bluebird bio
or or view top insider-buying stocks.

How do I buy shares of bluebird bio?

Shares of BLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is bluebird bio's stock price today?

One share of BLUE stock can currently be purchased for approximately $46.59.

How big of a company is bluebird bio?

bluebird bio has a market capitalization of $3.09 billion and generates $44.67 million in revenue each year. The biotechnology company earns $-789,610,000.00 in net income (profit) each year or ($14.31) on an earnings per share basis. bluebird bio employs 1,090 workers across the globe.

What is bluebird bio's official website?

The official website for bluebird bio is www.bluebirdbio.com.

How can I contact bluebird bio?

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 339-499-9300 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.